Literature DB >> 26535760

Buspirone: Back to the Future.

Robert H Howland.   

Abstract

Buspirone, first synthesized in 1968 and marketed in 1986, is a pharmacologically unique azapirone drug. It is effective for treating generalized anxiety, but not other anxiety disorders. Buspirone also is efficacious for depression, either alone or together with an antidepressant drug, and for treating adverse sexual effects. Studies of buspirone for substance use disorders have had disappointing outcomes, although it may be useful for treating coexisting anxiety and one controlled study suggested efficacy for heroin detoxification. Buspirone may be considered a treatment option for managing irritability, agitation, and aggression in older adult patients with dementia as well as in pediatric patients, although additional effectiveness studies are warranted. Buspirone and melatonin may synergistically promote neurogenesis, supporting the potential use of this combination for treating depression and cognitive impairment. Copyright 2015, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26535760     DOI: 10.3928/02793695-20151022-01

Source DB:  PubMed          Journal:  J Psychosoc Nurs Ment Health Serv        ISSN: 0279-3695            Impact factor:   1.098


  6 in total

1.  Functional Interrogation of a Depression-Related Serotonergic Single Nucleotide Polymorphism, rs6295, Using a Humanized Mouse Model.

Authors:  Ashley M Cunningham; Tabia L Santos; Vanessa A Gutzeit; Heather Hamilton; René Hen; Zoe R Donaldson
Journal:  ACS Chem Neurosci       Date:  2019-02-12       Impact factor: 4.418

2.  Pharmacological Management of Anxiety Disorders in the Elderly.

Authors:  Elizabeth A Crocco; Sindy Jaramillo; Caroline Cruz-Ortiz; Katherine Camfield
Journal:  Curr Treat Options Psychiatry       Date:  2017-02-10

3.  New-Onset Sleepwalking in a Patient Treated With Buspirone.

Authors:  Tabitha E H Moses; Arash Javanbakht
Journal:  J Clin Psychopharmacol       Date:  2022 Jan-Feb 01       Impact factor: 3.153

Review 4.  Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.

Authors:  María S García-Gutiérrez; Francisco Navarrete; Ani Gasparyan; Amaya Austrich-Olivares; Francisco Sala; Jorge Manzanares
Journal:  Biomolecules       Date:  2020-11-19

5.  Serotonin 1A agonist and cardiopulmonary improvements with whole-body exercise in acute, high-level spinal cord injury: a retrospective analysis.

Authors:  Isabelle Vivodtzev; Glen Picard; Kevin O'Connor; J Andrew Taylor
Journal:  Eur J Appl Physiol       Date:  2020-10-24       Impact factor: 3.078

6.  Buspirone in the management of refractory irritable bowel syndrome: A case report.

Authors:  Mustafa Abdul Karim; Nadeen Al-Baz; Peter M Haddad; Shuja M Reagu; Majid Alabdulla
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.